Merck announced on October 17, 2024, that its experimental antibody therapy, clesrovimab, demonstrated 60.4% effectiveness in reducing respiratory syncytial virus (RSV) infections in infants during a mid-late stage study.
This positive efficacy data is a crucial step towards potential regulatory approval for clesrovimab. If approved, this therapy could offer a new preventative option for infants against RSV, a common cause of hospitalization.
The strong results highlight Merck's commitment to expanding its vaccine and infectious disease portfolio. This development positions the company to address a significant unmet medical need in pediatric health.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.